Adrian Rawcliffe, Adaptimmune CEO
November 11, 2021 05:04 PM EST
R&D

Adap­ti­m­mune says it's (near­ly) ready to head to the FDA with TCR can­cer ther­a­py

Max Gelman

Senior Editor

Six months af­ter an ini­tial re­veal at AS­CO, Adap­ti­m­mune is back in the lime­light with new da­ta Thurs­day. And the com­pa­ny be­lieves it now …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Bio­haven's myo­statin in­hibitor miss­es pri­ma­ry end­point in spinal mus­cu­lar at­ro­phy tri­al

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

A service from the Financial Times